Fig. 1: Overview of study design to detect and characterize the hCRISPRs.

Schematic flowchart highlighting the major steps of the in silico approach as employed in this study. The major steps can be grouped as the following; identification of CRISPRs in the human reference genome (GRCh38); genomic characterization of the identified hCRISPRs (n = 12,572); expression and the discovery of a diagnostic potential for the hCRISPRs in cell lines, distinct human tissues (Illumina Bodymap 2.0 and DASHR 2.0), prostate cancer (NGS-ProToCol), and a pan-cancer (localized) cohort (MiTranscriptome).